Panbela Therapeutics Precio/Valor contable
¿Qué es el Precio/Valor contable de Panbela Therapeutics?
El Precio/Valor contable de Panbela Therapeutics Inc. es -0.13
¿Cuál es la definición de Precio/Valor contable?
El ratio precio-valor contable representa la relación entre el valor de las acciones de una empresa y el valor contable por acción.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Precio/Valor contable de compañías en Sector Health Care en NASDAQ en comparadas con Panbela Therapeutics
¿Qué hace Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Empresas con precio/valor contable similar a Panbela Therapeutics
- Personas Social tiene Precio/Valor contable de -0.13
- Zhongtian International tiene Precio/Valor contable de -0.13
- Pintec Technology Ltd tiene Precio/Valor contable de -0.13
- Aladdin Healthcare Technologies SE tiene Precio/Valor contable de -0.13
- Orchestra-Premaman S.A tiene Precio/Valor contable de -0.13
- IDT International tiene Precio/Valor contable de -0.13
- Panbela Therapeutics tiene Precio/Valor contable de -0.13
- Shirpur Gold Refinery tiene Precio/Valor contable de -0.13
- Guangdong Adway Construction () tiene Precio/Valor contable de -0.13
- ParcelPal Technology tiene Precio/Valor contable de -0.13
- Rentian Technology tiene Precio/Valor contable de -0.13
- Diebold Nixdorf Inc tiene Precio/Valor contable de -0.12
- Jaypee Infratech tiene Precio/Valor contable de -0.12